Page 2 - Dupilumab Development Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Sanofi: Dupixent recommended for EU approval by the CHMP to treat patients with COPD

Dupixent recommended for EU approval by the CHMP to treat patients with COPD Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3

France generalUnited statesCorentine driancourtTimothy gilbertSandrine guendoulVesna tosicFelix lauscherNathalie phamTarik elgoutniEvan berlandHannah kwaghThomas kudsk larsenEuropean commission of dupixentRegeneron genetics centerEuropean commissionClinical research program

Update On FDA Priority Review Of Dupixent® (Dupilumab) For The Treatment Of COPD Patients With Type 2 Inflammation

TARRYTOWN, N.Y. and PARIS, May 31, 2024 (GLOBE NEWSWIRE) Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food a

United statesFrance generalRegeneron velocimmuneGeorged yancopoulosClinical research programUs department of justiceExchange commissionDupilumab development programCommittee for medicinal products human useRegeneron pharmaceuticals incDrug administrationEuropean unionRegeneron genetics centerEuropean medicines agencyBiologics license applicationMedicinal products

Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine

NOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic.

United statesFrance generalArnaud delepineSurya bhattTimothy gilbertTarik elgoutniCorentine driancourtNathalie phamRegeneron velocimmuneEvan berlandHanna hodgeVesna tosicThomas kudsk larsenGeorged yancopoulosFelix lauscherAmerican thoracic society

Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM

Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesFrance generalTimothy gilbertSurya bhattCorentine driancourtTarik elgoutniNathalie phamEvan berlandThomas kudsk larsenHanna hodgeVesna tosicFelix lauscherExchange commissionUniversity of alabama at birminghamRegeneron genetics centerUs department of justice

Dupixent® (dupilumab) Late-Breaking Data from NOTUS

NOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% and improved lung function,.

United statesFrance generalRegeneron velocimmuneSurya bhattGeorged yancopoulosAmerican thoracic societyInternational conferenceDivision of pulmonaryUs department of justiceRegeneron genetics centerExchange commissionUniversity of alabama at birminghamClinical research programRegeneron pharmaceuticals incDupilumab development programEuropean union